You are here: Industry Insights > Xeris

News List

Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke Kit for the Treatment of Severe Hypoglycemia drugs
August 25, 2021
Xeris today announced that its supplemental new drug application (sNDA) of Gvoke® Kit was approved by the Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success firstwordpharma
July 29, 2021
Xeris today announced executive changes as part of its strategy to position the company for long-term commercial success, including the anticipated closing of the Strongbridge Biopharma plc acquisition and evolution to a more commercially driven company.
Xeris to Acquire Strongbridge Biopharma contractpharma
May 25, 2021
The two businesses will be combined under a new entity called Xeris Biopharma Holdings, specializing in endocrinology and rare diseases.
Xeris Receives European Commission Approval of Ogluo for Hypoglycemia americanpharmaceuticalreview
February 22, 2021
Xeris Pharmaceuticals announced the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke drugs
June 14, 2019
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke.
Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon pharmafocusasia
November 27, 2018
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Raises $55M for Glucagon Rescue Pen biospace
March 12, 2018
Xeris Pharmaceuticals, Inc. secured $45 million in a Term Loan and Securities Agreement with Silicon Valley Bank and Oxford Finance, as well as closing a Series C financing with an additional $10 million.